Whereas, it is desirable to conduct a study concerning the State's pharmaceutical markets;

Whereas, unless this legislation is enacted as an emergency, there will not be sufficient time in which to complete the study before the Second Regular Session of the 119th Legislature; and

Whereas, in the judgment of the Legislature, these facts create an emergency within the meaning of the Constitution of Maine and require the following legislation as immediately necessary for the preservation of the public peace, health and safety; now, therefore, be it

Sec. 1. Advisory committee. Resolved: That there is established an advisory committee known as Maine's Business Advisory Committee on Prescription Drug Costs and Efficiencies, referred to in this resolve as the "committee"; and be it further

Sec. 2. Membership. Resolved: That the committee consists of 13 members appointed as follows:

1. Two members of the Senate, of which one represents the minority party, appointed by the President of the Senate;

2. Two members of the House of Representatives, of which one represents the minority party, appointed by the Speaker of the House;

3. The Commissioner of the Department of Human Services or the commissioner's designee;

4. The Commissioner of Professional and Financial Regulation or the commissioner's designee;

5. One representative from the Maine Congressional Delegation, appointed by the President of the Senate;

6. One representative from a statewide health management organization, appointed by the President of the Senate;

7. One representative from a statewide senior citizen organization, appointed by the Speaker of the House;

8. One representative from a drug manufacturing business, appointed by the Speaker of the House;